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A 46-year-old Caucasian male was admitted in June 2007 for a
recent history of headaches and fever. He had been treated for
Behc¸et’s disease for the past seven years, with recurrent oral
aphtosis, diffuse arthralgias and severe uveitis. Unusual severe
bilateral uveitis prompted us to give oral corticosteroids for 30
months, infliximab for 18 months and mycophenolate mofetil
(2 g/day) for 14 months. Infliximab was started in January
2006 at a dose of 3 mg/kg/infusion (250 mg) and then 5 mg/
kg/infusion (400 mg) in January 2007. The patient had
received his nineteenth infusion 15 days before admission.
Physical examination was normal. Laboratory tests were
within normal ranges. Brain and full-body CTscans, brain MRI
and electroencephalogram were normal. Cerebrospinal fluid
(CSF) contained 5 white blood cells/mm3, the glucose level
was 4.4 mmol/l and protein concentration was 0.44 g/l. Gram
staining was negative. Blood and CSF cultures were negative.
Two weeks later, the headaches and intermittent fever
persisted and were attributed to active Behc¸et’s disease. An
infusion of infliximab was performed. Four days later, the
patient developed sudden bilateral hearing loss, left transient
hemiplegia, confusion and apraxia. Laboratory tests revealed
7600 neutrophils/mm3 and lymphopenia (623/mm3). CSF ana-
lysis revealed meningitis, with 189 leukocytes/mm3 (67% lym-
phocytes, 20% polymorphonuclear cells and 13% monocytes/
macrophages). Protein content was 0.54 g/l and the glucose
level was 0.67 mmol/l. Direct examination with India ink
staining identified Cryptococcus neoformans.
A combination of intravenous amphotericin B with flucy-
tosine was prescribed for two weeks, followed by oral flu-
conazole. Infliximab was stopped, but both corticosteroids
and mycophenolate mofetil were maintained. At a six-month
follow-up, no infectious relapse had occurred.
The patient, who lived on a farm, had recurrent contact
with avian excreta, a potential source of C. neoformans,
because of his occupation involving battery-reared pigeons.
To date, only two cases of cryptococcal meningitis in
patients treated with infliximab have been reported;1,2 in
our case, the combination of several immunosuppressive
therapies for a prolonged time makes it difficult to assess
the respective roles of each drug.3 Cases of opportunistic
infections by Cryptococcus have also been reported in solid-
organ transplant patients treated with mycophenolate mofe-1201-9712/$36.00 # 2009 Published by Elsevier Ltd on behalf of Intern
doi:10.1016/j.ijid.2008.11.007til;4,5 our patient had been treated with this drug for the past
14 months.
This case reminds us that patients undergoing such immu-
nosuppressive therapies should be given some recommenda-
tions, such as avoiding close and repeated contact with avian
excreta and potentially contaminated soils.
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